Substance / Medication

Brexanolone

Overview

Active Ingredient
brexanolone
RxNorm CUI
2121777

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

2 trials linked to this intervention

2
Total Trials
1
Recruiting
1
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Brexanolone, zuranolone and related neurosteroid GABAreceptor positive allosteric modulators for postnatal depression.
Wilson Claire A, Robertson Lindsay, Ayre Karyn et al. · Cochrane Database Syst Rev · 2025
PMID: 40562419Meta-AnalysisFull text (PMC)
Brexanolone in Postpartum Depression:Analyses to Help Inform Clinical Decision-Making.
Gerbasi Margaret E, Meltzer-Brody Samantha, Acaster Sarah et al. · J Womens Health (Larchmt) · 2021
PMID: 33181049Meta-AnalysisFull text (PMC)
Brexanolone for postpartum depression: A meta-analysis of randomized controlled studies.
Zheng Wei, Cai Dong-Bin, Zheng Wei et al. · Psychiatry Res · 2019
PMID: 31323375Meta-Analysis
A systematic analysis of safety profile of Brexanolone in real-world use based on FAERS database.
Jiang Ying, Wang Shuai, Du Zhiqiang et al. · J Affect Disord · 2025
PMID: 40258423Other
Safety assessment of brexanolone in the FAERS database: real adverse event analysis and discussion of side effects.
Jin Liuyin, Yang Kaixia, Wu Xiping et al. · Expert Opin Drug Saf · 2025
PMID: 39093352Other
A retrospective chart review study of patients treated in a hospital-based brexanolone program.
Diaz Zobeida M, Howard Margaret M, Moreno Keyline V et al. · Arch Womens Ment Health · 2025
PMID: 40312466Other
Racial and ethnic diversity in zuranolone and brexanolone clinical trials for postpartum depression: A cross-sectional analysis of ClinicalTrials.gov.
Swieczkowski Damian, Kwaśny Aleksander, Pruc Michal et al. · Eur Neuropsychopharmacol · 2025
PMID: 40220578Other
Real-World Outcomes of Brexanolone to Treat Postpartum Depression.
Barrett Melanie, Hettema Jennifer, Youngman Constance et al. · Womens Health Rep (New Rochelle) · 2025
PMID: 41142477OtherFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Brexanolone (substance)
SNOMED CT
787054008
UMLS CUI
C4548848
RxNorm CUI
2121777

Clinical Data

This intervention maps to 1 entities in the Healos knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
2
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.